Chronic Pulmonary Hypertension Treatment Market Report 2026

Chronic Pulmonary Hypertension Treatment Market Overview

• Chronic Pulmonary Hypertension Treatment market size has reached to $7.19 billion in 2025 • Expected to grow to $9.34 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Impact Of The High Burden Of Cardiovascular Diseases On The Growth Of The Market • Market Trend: Focus On Subcutaneous Injections And FDA Approvals • North America was the largest region in 2025.

What Is Covered Under Chronic Pulmonary Hypertension Treatment Market?

Chronic pulmonary hypertension (PH) treatment refers to managing elevated blood pressure in the lungs to improve heart function and quality of life. It includes medications to reduce pressure, oxygen therapy, and diuretics to ease symptoms. Advanced treatments involve pulmonary rehabilitation, lifestyle modifications, and medical procedures if necessary. In severe cases, surgical interventions may be considered. The main drug types of chronic pulmonary hypertension include endothelin receptor antagonists (ERAs), phosphodiesterase (PDE-5) inhibitors, prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. ERAs are drugs that block endothelin to treat pulmonary hypertension and improve the quality of life. These drugs are administered through various routes, including oral, intravenous, subcutaneous, and inhalational, and distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Chronic Pulmonary Hypertension Treatment Market Growth Forecast?

The chronic pulmonary hypertension treatment market size is expected to see strong growth in the next few years. It will grow to $9.34 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing approvals of novel PH drugs, rising investment in rare disease therapies, growing adoption of inhalational drug delivery, expansion of telemedicine-based disease management, increasing focus on patient-centric care models. Major trends in the forecast period include increasing adoption of targeted pulmonary hypertension drugs, rising use of combination therapy regimens, growing focus on early diagnosis and disease monitoring, expansion of home-based oxygen and supportive therapies, enhanced emphasis on personalized treatment protocols.

What Is The Driver Of The Chronic Pulmonary Hypertension Treatment Market?

The high burden of cardiovascular diseases is expected to propel the growth of the chronic pulmonary hypertension treatment market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The high burden of cardiovascular diseases is attributed to risk factors such as unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, obesity, hypertension, diabetes, and aging populations. Chronic pulmonary hypertension treatment supports cardiovascular health by lowering pulmonary artery pressure, enhancing heart function, and reducing the risk of heart failure and related complications. For instance, in August 2025, according to the National Institutes of Health, a US-based government agency, between 2025 and 2050, cardiovascular prevalence is projected to rise by 90%, mortality by 73%, and DALYs by 55%, with deaths increasing from 20.5 million to 35.6 million. Therefore, the high burden of cardiovascular diseases is driving the growth of the chronic pulmonary hypertension treatment industry.

Key Players In The Global Chronic Pulmonary Hypertension Treatment Market

Major companies operating in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, Liquidia Technologies

Global Chronic Pulmonary Hypertension Treatment Market Trends and Insights

Major companies operating in the chronic pulmonary hypertension treatment market are focusing on innovative solutions, such as subcutaneous injection, to enhance patient compliance, improve convenience, and provide more targeted treatment options. Subcutaneous injection delivers continuous medication under the skin to help lower pulmonary artery pressure and improve blood flow in pulmonary hypertension patients. For instance, in March 2024, Merck & Co Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Winrevair (sotatercept-csrk), marking a significant advancement in pulmonary arterial hypertension (PAH) treatment. This innovative therapy offers unique benefits, distinguishing it as a groundbreaking option for PAH. Clinical trials have demonstrated that Winrevair improves WHO functional class in 29% of patients, compared to 14% in the placebo group, leading to an overall enhancement in quality of life.

What Are Latest Mergers And Acquisitions In The Chronic Pulmonary Hypertension Treatment Market?

In October 2024, Liquidia Corporation, a US-based biopharmaceutical company, partnered with Pharmosa Biopharm to expand the development and commercialization of L606. With this partnership, Liquidia Corporation and Pharmosa Biopharm aim to advance the development and commercialization of L606, an inhaled treprostinil therapy, to improve treatment options for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Pharmosa Biopharm is a Taiwan-based biotechnology company that specializes in the research, development, and commercialization of pharmaceuticals and medical devices.

What Defines the Chronic Pulmonary Hypertension Treatment Market?

The chronic pulmonary hypertension treatment market consists of revenues earned by entities by providing services such as pharmacological treatment services, cardiopulmonary rehabilitation, telemedicine and remote patient monitoring, oxygen therapy, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pulmonary hypertension treatment market also includes sales of calcium channel blockers, pulmonary artery pressure monitoring systems, inhalation devices, and oxygen therapy equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Pulmonary Hypertension Treatment Market Report 2026?

The chronic pulmonary hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pulmonary hypertension treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.